Insmed reported $414.63M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
DBV Technologies DBVT:US USD 44.75M 23.46M
Acelrx Pharmaceuticals ACRX:US USD 12.73M 2.43M
Alimera Sciences ALIM:US USD 5.51M 2.34M
Biomarin Pharmaceutical BMRN:US USD 761.52M 141.71M
Cytokinetics CYTK:US USD 106.24M 12.61M
Dynavax Technologies DVAX:US USD 586.49M 337.4M
Gilead Sciences GILD:US USD 7.63B 2.93B
Heron Therapeutics HRTX:US USD 50.44M 1.83M
Insmed INSM:US USD 414.63M 1.44M
Mirati Therapeutics MRTX:US USD 173.53M 71.97M
Novartis NVS:US USD 7.52B 1.21B
Ophthotech OPHT:US USD 153.1M 11.99M
Regeneron Pharmaceuticals REGN:US USD 14.33B 10.84B
Sarepta Therapeutics SRPT:US USD 1.04B 170.06M
Seattle Genetics SGEN:US USD 362.6M 2.27M
Ultragenyx Pharmaceutical RARE:US USD 391.65M 231.78M
Vertex Pharmaceuticals VRTX:US USD 9.17B 469.3M